Cochrane Database Syst Rev January 2014 PMID 24395698

Chlorpromazine versus placebo for schizophrenia.

Clive E Adams, George A Awad, John Rathbone, Ben Thornley, Karla Soares-Weiser

Full text PDF Download social card

Mentions

Peak: 1 in Dec 2015

across 4 sources since Dec 2015

Extended reach

60,756

potential audience

Total likes

307

Video views

60,597

Mentions per month

Dec 2015 – May 2022

Where it's discussed

Blogs3 articles
Facebook2 posts
X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a balanced attitude, with some users mentioning that chlorpromazine may reduce relapse rates and improve symptoms, as seen in phrases like 'may help' and 'could be beneficial'. The tone indicates recognition of the study's importance but lacks detailed critique or extensive debate, which explains the moderate scores in agreement and impact.

AgreementModerate agreement

Many discussions acknowledge the findings, with some expressing cautious support for chlorpromazine's benefits, reflecting moderate agreement.

InterestModerate interest

The discussions show moderate curiosity about the research, indicating some participants find the topic relevant or noteworthy.

EngagementNeutral engagement

Most comments are brief, with limited detailed analysis or critique, suggesting low to moderate engagement.

ImpactModerate impact

The posts imply that the study could influence clinical considerations, but they do not demonstrate widespread or deep recognition of its transformative potential.

Abstract in brief

This review analyzed multiple randomized controlled trials to compare chlorpromazine with placebo for treating schizophrenia, focusing on outcomes like relapse, symptom improvement, and safety, but found the overall evidence quality to be very low.
Results indicated that chlorpromazine may reduce relapse rates over a 6-month to 2-year period; however, the findings were inconsistent and data heterogeneity made conclusions uncertain.
The study also showed that chlorpromazine might improve overall symptoms and functioning in patients, but no significant difference was observed in long-term relapse rates beyond two years.

Read the full abstract

All mentions

Chlorpromazine Effectiveness and Safety in Schizophrenia Treatment

This video reviews the evidence on chlorpromazine's effects, safety, and its comparison with placebo and haloperidol for schizophrenia. Based on systematic reviews, it discusses its potential to reduce relapse and…

Cochrane · Dec 2, 2015 60,597 views

Hans Bangen - Psychiatrie / Psychiatry

@HansBangen · X

Chlorpromazine versus placebo for schizophrenia https://t.co/z85PjCqhBn #Schizophrenie #Schizophrenia

May 23, 2022 · 1 like · 159 followers View post →